PATENT CLAIM ANALYSIS

Application Number: 15969383
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["546", "273700"]

Abstract:
The present invention relates to a process for the preparation of anhydrous crystalline 2-(R)-[(3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl]-1H-benzimidazole (dexlansoprazole).

Claim (Index 20):
A composition according to  claim 18  comprising crystalline anhydrous dexlansoprazole, characterized by an XRPD pattern having peaks at 7.5, 11.4, 13.1, 13.5, 15.1, 15.4, 17.3, 20.0, 21.7, 22.5, 24.0, 26.1, 27.3 and 28.6\u00b10.2\u00b0 in 2\u03b8, with a purity equal to or higher than 99%, in combination with an impurity of formula (I) in quantities equal to or lower than 0.03%, calculated as HPLC area % (A %) at 285 nm.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 93.0
- Lexical Diversity: 1.25
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12830713', '15501908', '12693539', '12356004', '12283702']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7568499724807055
- 35 USC 102 Novelty (BERT): 0.5728780827233828
- Combined Prediction Score: 0.7384527835049732
- Mean Citation Score: 264.91933400000005
- Max Citation Score: 486.37616
- Similarity Product: 398.8240991794301

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test